NASDAQ:RAPP Rapport Therapeutics (RAPP) Stock Price, News & Analysis $18.07 +0.21 (+1.18%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends About Rapport Therapeutics Stock (NASDAQ:RAPP) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Rapport Therapeutics alerts:Sign Up Key Stats Today's Range$17.52▼$19.0850-Day Range$17.86▼$29.2352-Week Range$16.55▼$29.74Volume527,558 shsAverage Volume155,880 shsMarket Capitalization$660.93 millionP/E RatioN/ADividend YieldN/APrice Target$35.00Consensus RatingBuy Company OverviewRapport Therapeutics Inc. is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc. is based in BOSTON.Read More… Rapport Therapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks31st Percentile Overall ScoreRAPP MarketRank™: Rapport Therapeutics scored higher than 31% of companies evaluated by MarketBeat, and ranked 795th out of 947 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingRapport Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageRapport Therapeutics has received no research coverage in the past 90 days.Read more about Rapport Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Rapport Therapeutics are expected to grow in the coming year, from ($3.65) to ($3.37) per share. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.25% of the float of Rapport Therapeutics has been sold short.Short Interest Ratio / Days to CoverRapport Therapeutics has a short interest ratio ("days to cover") of 12.3, which indicates bearish sentiment.Change versus previous monthShort interest in Rapport Therapeutics has recently increased by 2.87%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldRapport Therapeutics does not currently pay a dividend.Dividend GrowthRapport Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted10.25% of the float of Rapport Therapeutics has been sold short.Short Interest Ratio / Days to CoverRapport Therapeutics has a short interest ratio ("days to cover") of 12.3, which indicates bearish sentiment.Change versus previous monthShort interest in Rapport Therapeutics has recently increased by 2.87%, indicating that investor sentiment is decreasing. News and Social Media2.0 / 5News Sentiment0.56 News SentimentRapport Therapeutics has a news sentiment score of 0.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Rapport Therapeutics this week, compared to 2 articles on an average week. Company OwnershipN/AInsider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Rapport Therapeutics insiders have not sold or bought any company stock.Read more about Rapport Therapeutics' insider trading history. Receive RAPP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Rapport Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address RAPP Stock News HeadlinesRapport Therapeutics management to meet with TruistDecember 6, 2024 | tipranks.comRapport Therapeutics presents data on long episode seizure biomarkerDecember 6, 2024 | tipranks.comWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indicates the Oracle of Omaha is quietly preparing for a historic market crash. His most reliable crash indicator - the "Buffett indicator" - just flashed red for the first time in 25 years.December 21, 2024 | Behind the Markets (Ad)Rapport Therapeutics Presents Data Demonstrating Consistent Association Between Decreases in RNS Measured Long Episodes and Meaningful Reductions in Clinical SeizuresDecember 6, 2024 | globenewswire.comRapport Therapeutics to Present Data at American Epilepsy Society Annual MeetingNovember 14, 2024 | globenewswire.comRapport Therapeutics Reports Q3 Financials and Strategic UpdatesNovember 9, 2024 | tipranks.comRapport Therapeutics to Present at Stifel Healthcare Conference and Jefferies London Healthcare Conference in NovemberNovember 4, 2024 | globenewswire.comRapport semestriel Pilier 3 - 30 juin 2024September 17, 2024 | globenewswire.comSee More Headlines RAPP Stock Analysis - Frequently Asked Questions How have RAPP shares performed this year? Rapport Therapeutics' stock was trading at $25.01 at the beginning of 2024. Since then, RAPP stock has decreased by 27.7% and is now trading at $18.07. View the best growth stocks for 2024 here. How were Rapport Therapeutics' earnings last quarter? Rapport Therapeutics (NASDAQ:RAPP) issued its quarterly earnings results on Thursday, August, 8th. The company reported ($1.70) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.68) by $1.02. When did Rapport Therapeutics IPO? Rapport Therapeutics (RAPP) raised $136 million in an initial public offering (IPO) on Friday, June 7th 2024. The company issued 8,000,000 shares at a price of $17.00 per share. When did Rapport Therapeutics' lock-up period expire? Rapport Therapeutics' lock-up period expired on Wednesday, December 4th. Rapport Therapeutics had issued 8,000,000 shares in its public offering on June 7th. The total size of the offering was $136,000,000 based on an initial share price of $17.00. Since the end of Rapport Therapeutics' lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company have been lifted. Who are Rapport Therapeutics' major shareholders? Rapport Therapeutics' top institutional shareholders include FMR LLC (15.00%), Geode Capital Management LLC (0.55%), Eventide Asset Management LLC (0.30%) and The Manufacturers Life Insurance Company (0.21%). View institutional ownership trends. How do I buy shares of Rapport Therapeutics? Shares of RAPP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Rapport Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Rapport Therapeutics investors own include Alpha Metallurgical Resources (AMR), Arch Resources (ARCH), Global X Copper Miners ETF (COPX), Hims & Hers Health (HIMS), Karuna Therapeutics (KRTX), Longboard Pharmaceuticals (LBPH) and Navios Maritime Partners (NMM). Company Calendar Last Earnings8/08/2024Today12/21/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:RAPP Previous SymbolNASDAQ:RAPP CUSIPN/A CIK2012593 WebN/A Phone(857) 321-8020FaxN/AEmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price Target$35.00 High Stock Price Target$35.00 Low Stock Price Target$35.00 Potential Upside/Downside+93.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio45.91 Quick Ratio45.91 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares36,576,000Free FloatN/AMarket Cap$660.93 million OptionableN/A BetaN/A Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report This page (NASDAQ:RAPP) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rapport Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share Rapport Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.